Kymera Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Kymera Therapeutics, Inc. on June 16, 2021. The company is an emerging growth company incorporated in Delaware, with its common stock traded on The Nasdaq Global Market under the symbol KYMR.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Class I Directors
- Pamela Esposito, Ph.D.: Elected with 27,282,245 votes for, 1,414,104 withheld, and 4,600,594 broker non-votes.
- Gorjan Hrustanovic, Ph.D.: Elected with 22,792,028 votes for, 5,904,321 withheld, and 4,600,594 broker non-votes.
- Donald W. Nicholson, Ph.D.: Elected with 25,476,273 votes for, 3,220,076 withheld, and 4,600,594 broker non-votes.
- All three directors were elected for a three-year term ending in 2024.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Votes For: 33,293,365
- Votes Against: 130
- Abstain: 3,448
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. No other matters were submitted to a vote.
Key Facts for Investor Verification
- Confirmation of the three-year term for the newly elected Class I directors.
- Verification of the significant number of broker non-votes (4,600,594) recorded for the director elections.
- Confirmation that Ernst & Young LLP remains the auditor for the 2021 fiscal year.